Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Kathleen Van AstenLaurence SlembrouckSiel OlbrechtLynn JongenOlivier BrouckaertHans P M W WildiersGiuseppe FlorisErik Van LimbergenCaroline WeltensAnn SmeetsRobert ParidaensAnita Giobbie-HurderMeredith M ReganGiuseppe VialeBeat ThürlimannIgnace VergoteEvangelia ChristodoulouBen Van CalsterPatrick NevenPublished in: The oncologist (2018)
An absent progesterone receptor (PR) predicts a worse outcome in women treated for an estrogen receptor-positive, human epidermal growth factor receptor 2 negative breast cancer. As low proliferative tumors lacking PR are now also classified high risk, the prognostic value of PR across risk groups was studied. Despite a negative test for interaction of the prognostic value of PR by tumor grade, the magnitude of an absent PR on breast cancer relapse is much larger in high than in low proliferative breast cancers.